SCHEMBL25215331

SCHEMBL25215331

O=[N+]([O-])c1cc2c(Nc3ccnc(-c4ccccc4F)c3)ncnc2cc1OCCCN1CCN(CCOC2CCCCO2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHA2 P29317 1/20 0.45
▸ EGFR P00533 19/20 0.45
▸ AURKA O14965 2/20 0.43
▸ PDGFRB P09619 2/20 0.43
▸ TEK Q02763 2/20 0.43
▸ AURKB Q96GD4 2/20 0.43
▸ ERBB2 P04626 2/20 0.43
▸ FLT4 P35916 2/20 0.43
▸ KDR P35968 2/20 0.43
▸ CIT O14578 1/20 0.41
▸ GAK O14976 1/20 0.41
▸ EPHB6 O15197 1/20 0.41
▸ ABCC4 O15439 1/20 0.41
▸ DAPK3 O43293 1/20 0.41
▸ RIPK2 O43353 1/20 0.41
▸ NR1I2 O75469 1/20 0.41
▸ RPS6KA4 O75676 1/20 0.41
▸ STK17B O94768 1/20 0.41
▸ STK10 O94804 1/20 0.41
▸ PRKD3 O94806 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25663602 0.89 EPHA2 (0.47) EPHA2EGFRAURKAPDGFRBTEK
SCHEMBL30428787 0.89 EPHA2 (0.47) EPHA2EGFRAURKAPDGFRBTEK
SCHEMBL26055501 0.86 EGFR (0.51) EGFRAURKAPDGFRBTEKAURKB
SCHEMBL25213685 0.85 EGFR (0.58) EGFRPDGFRBAURKBERBB2KDR
SCHEMBL25663596 0.85 EGFR (0.47) EGFRAURKAPDGFRBTEKAURKB
SCHEMBL25215929 0.84 EGFR (0.53) EGFRAURKAPDGFRBTEKAURKB
SCHEMBL25220782 0.84 EGFR (0.49) EGFRAURKAPDGFRBTEKAURKB
SCHEMBL25246042 0.83 EGFR (0.48) EGFRAURKAPDGFRBTEKAURKB
SCHEMBL28969396 0.80 EGFR (0.46) EGFRAURKAPDGFRBTEKAURKB
SCHEMBL26055465 0.79 EGFR (0.47) EPHA2EGFRERBB2KDRMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271936-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-08-31 — — US disclosed
EP-4194443-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2023-06-14 — — EP disclosed
CN-115803325-A EGFR inhibitor and preparation method and application thereof 上海和誉生物医药科技有限公司 2023-03-14 — — CN disclosed
WO-2022033410-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 上海和誉生物医药科技有限公司 2022-02-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271936-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF EGFR, WEE1, WEE2 EPHA2 171/4885EGFR 1/4885AURKA 2179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback